Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
28
Recruiting, industry sponsors, Cardiovascular and metabolic, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed906
28 trials
Showing 1 to 25, recently updated first.
Eidos Therapeutics, a BridgeBio companyIndustry
NCT07695701 · 150 participants (planned) · Start Jul 28, 2026 · Primary completion Aug 2030
Drug: Acoramidis (AG10) oral tablet · For: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM); Amyloidosis; Amyloid Cardiomyopathy and 1 more
Sites: Baltimore, Maryland; St Louis, Missouri; Philadelphia, Pennsylvania · 9 sites in all
BayerBayer (BAYRY)
NCT07298044 · 50 participants (planned) · Start Feb 13, 2026 · Primary completion Sep 17, 2027
Drug: Acoramidis · For: Transthyretin Amyloid Cardiomyopathy
Sites: Sankt Pölten, Austria; Vienna, Austria; Braunau am Inn, Austria · 26 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07600723 · 30 participants (planned) · Start Oct 8, 2026 · Primary completion Apr 3, 2028
Drug: Sotatercept; Background PAH Therapy · For: Pulmonary Arterial Hypertension
Sites: Hyderabad, India; Belagavi, India; Chennai, India
Eli Lilly and CompanyEli Lilly (LLY)
NCT06857942 · 200 participants (planned) · Start Mar 19, 2025 · Primary completion May 2028
Drug: Tirzepatide · For: Psoriasis; Overweight or Obesity
Sites: Phoenix, Arizona; Fountain Valley, California; Fremont, California · 38 sites in all
- Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's SyndromeRecruiting
RECORDATI GROUPIndustry
NCT07247162 · 63 participants (planned) · Start Aug 26, 2026 · Primary completion May 2028
Drug: Osilodrostat; Placebo · For: Hypertension; Hypercortisolemia; Cushing Syndrome
Sites: Jacksonville, Florida; Canton, Ohio; Weslaco, Texas
- Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I PatientsPivotal-lookingRecruiting
AOP Orphan Pharmaceuticals AGIndustry
NCT06317805 · 110 participants (planned) · Start Dec 6, 2023 · Primary completion Jun 2027
Drug: Generic treprostinil sodium + Standard of Care (Double Oral); Standard of Care - Double Oral · For: Pulmonary Arterial Hypertension
Sites: Bahía Blanca, Argentina; Buenos Aires, Argentina; La Plata, Argentina · 28 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07900438 · 300 participants (planned) · Start Oct 12, 2026 · Primary completion Dec 20, 2029
Drug: Semaglutide · For: Cardiovascular Risk; Chronic Kidney Disease
Sites: Fuyang, China; Beijing, China; Lanzhou, China · 26 sites in all
EVD Pharmacy and Medical Company LimitedIndustry
NCT07828210 · 80 participants (planned) · Start Sep 10, 2026 · Primary completion Sep 2027
Drug: MLC901 · For: Stroke; Stroke, Acute Ischemic; Stroke, Ischemic and 2 more
Sites: Ho Chi Minh City, Vietnam
AstraZenecaAstraZeneca (AZN)
NCT06651970 · 60 participants (planned) · Start Feb 4, 2025 · Primary completion Sep 30, 2032
Drug: Acalabrutinib · For: Chronic Lymphocytic Leukaemia; Moderate to Severe Cardiac Impairment
Sites: Charlotte, North Carolina; Columbus, Ohio; Philadelphia, Pennsylvania · 23 sites in all
- A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07247084 · 3,000 participants (planned) · Start Nov 24, 2025 · Primary completion Jul 2029
Drug: Tirzepatide · For: Obesity
Sites: Altrincham, United Kingdom; Ashton-under-Lyne, United Kingdom; Bolton, United Kingdom · 30 sites in all
- A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 DiabetesPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07112339 · 586 participants (planned) · Start Aug 15, 2025 · Primary completion Mar 23, 2028
Drug: Insulin icodec; Basal insulin analogues · For: Diabetes Mellitus, Type 2
Sites: Calgary, Canada; Edmonton, Canada; New Westminster, Canada · 75 sites in all
Gila Therapeutics, Inc.Industry
NCT07728383 · 40 participants (planned) · Start Jun 17, 2026 · Primary completion May 2027
Drug: Semaglutide 6 mg liquid emulsion formulation; Wegovy® (semaglutide) Tablet and 1 more · For: Obesity & Overweight
Sites: Minneapolis, Minnesota
- A Post-Marketing Clinical Trial of Pemafibrate in Patients with Hypercholesterolemia and Inadequate Response to StatinsPivotal-lookingRecruiting
Kowa Company, Ltd.Industry
NCT07634484 · 120 participants (planned) · Start Jul 1, 2026 · Primary completion Jul 31, 2027
Drug: Pemafibrate 0.2 mg/day; Pemafibrate 0.4 mg/day and 1 more · For: Hypercholesterolemia
Sites: Hokkaido, Japan; Ibaraki, Japan; Kagawa, Japan · 10 sites in all
- Travoprost Intraocular Implant + iStent InfinitePivotal-lookingRecruiting
Glaukos CorporationIndustry
NCT06066645 · 150 participants (planned) · Start Sep 14, 2023 · Primary completion May 2027
Drug: Travoprost Intraocular Implant · For: Glaucoma, Open-Angle
Sites: Oklahoma City, Oklahoma
- Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic StrokePivotal-lookingRecruiting
PharmasoftIndustry
NCT07575984 · 120 participants (planned) · Start Nov 4, 2025 · Primary completion Apr 2027
Drug: Mexidol; Glycine · For: Ischemic Stroke
Sites: Arkhangelsk, Russia; Ivanovo, Russia; Ryazan, Russia · 9 sites in all
- iGlarLixi CGM Study in Chinese T2D Individuals After OADsPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT06671587 · 678 participants (planned) · Start Dec 10, 2024 · Primary completion Sep 18, 2026
Drug: iGlarLixi (insulin glargine/lixisenatide); Gla-100 (insulin glargine) · For: Type 2 Diabetes (T2D)
Sites: Beijing, China
- Glycemic Variability of Combination Therapies in T2DMPivotal-lookingRecruiting
JW PharmaceuticalIndustry
NCT07442006 · 178 participants (planned) · Start Oct 29, 2025 · Primary completion Mar 31, 2027
Drug: Empagliflozin/Metformin; Anagliptin and 2 more · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Seoul, South Korea
Getz PharmaIndustry
NCT05164263 · 2,000 participants (planned) · Start Apr 1, 2021 · Primary completion Dec 31, 2026
Drug: Empagliflozin · For: Type II Diabetes Mellitus; Efficacy, Self; Safety Issues
Sites: Kabul, Afghanistan; Nairobi, Kenya; Lagos, Nigeria · 6 sites in all
BioXTekIndustry
NCT07326553 · 30 participants (planned) · Start Dec 1, 2025 · Primary completion Jul 31, 2026
Drug: Placental Membrane · For: Diabete Mellitus; Foot Ulcer Chronic
Sites: Phoenix, Arizona; Houston, Texas
- LATAM LOWERS LDL-CPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06501443 · 520 participants (planned) · Start Feb 11, 2025 · Primary completion Nov 27, 2026
Drug: Usual care; KJX839 · For: Hypercholesterolaemia
Sites: Corrientes, Argentina; Salvador, Brazil; Belo Horizonte, Brazil · 11 sites in all
- Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic ControlPivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07244003 · 430 participants (planned) · Start Mar 29, 2025 · Primary completion Dec 31, 2027
Drug: Metformin; Triple Therapy of Other Oral Antidiabetic Drugs and 2 more · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Tianjin, China
- Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.Pivotal-lookingRecruiting
Royal BiologicsIndustry
NCT07209475 · 248 participants (planned) · Start Aug 14, 2025 · Primary completion Aug 14, 2026
Drug: Amnio-Maxx® Dual Layer Amnion Patch · For: Diabetic Foot Ulcer (DFU); Amnio-Maxx
Sites: Burbank, California; Miami, Florida; Stone Mountain, Georgia · 8 sites in all
Ace Cells Lab LimitedIndustry
NCT07187713 · 300 participants (planned) · Start Sep 20, 2025 · Primary completion Aug 31, 2026
Drug: ACE Reno · For: Hypertensive Nephropathy; Auto Immune Disorders; Chronic Kidney Disease and 5 more
Sites: Giza, Egypt
- A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 DiabetesPivotal-lookingRecruiting
Boryung Pharmaceutical Co., LtdIndustry
NCT06972732 · 204 participants (planned) · Start Jun 11, 2025 · Primary completion Oct 1, 2026
Drug: Metformin; Dapagliflozin/Pioglitazone and 1 more · For: Type 2 Diabetes
Sites: Seoul, South Korea
Getz PharmaIndustry
NCT05644717 · 164 participants (planned) · Start Mar 1, 2023 · Primary completion Nov 1, 2025
Drug: Ertugliflozin 5 mg, 15mg · For: Liver Fat; Liver Fibrosis; Glycemic Control and 3 more
Sites: Peshawar, Pakistan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.